Blogs: Inappropriate at work, a protected right for employees
Employers in most states are allowed to discharge an employee for a good reason, bad reason or no reason at all, as long as it is not an illegal reason. One of the prohibited reasons for firing an employee is for engaging in some activity protected by law.
A "blog," short for "Web log," is an online personal journal kept by a writer. According to a November 2005 poll by the Dallas chapter of the International Association of Business Communicators, which conducts a monthly online Quick Poll on its Web site, 34% of respondents admitted to blogging at work or on a topic related to their workplace. As a new platform for communicating, it is also becoming more controversial, since anyone can create a blog for public viewing.
Risks employers face from employee blogging include: 1) possible disclosure of confidential information; 2) potential securities laws violations for disclosure of non-public information; 3) possible liability for torts committed by employees while blogging, including defamation of customers or competitors, invasion of privacy, etc.; 4) possible liability for harassment or discrimination claims; and/or 5) possible intellectual property infringement.
To protect against these risks, employers should tell employees several things.
If an employee/blogger is not using his or her real name, obtaining a court subpoena to learn the identity of an anonymous user has First Amendment implications. Courts recognize a right to speak anonymously on the Internet and have applied various balancing tests in determining whether the First Amendment prevents discovery of an anonymous user's identity.
Some of the more interesting cases involving bloggers have emanated from the healthcare arena. It is possible that the employee is engaging in protected activity in blogging under the NLRA, Title VII, whistleblower statutes, etc.
This column is written for informational purposes only and should not be construed as legal advice.
Barry Senterfitt is a partner in the insurance industry practice of Akin Gump Strauss Hauer & Feld LLP in the firm's Austin, Texas, office.
In this second part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein spoke with Ceci Connolly and Margaret "Meg" Murray about Medicare Advantage utilization and challenges, highlighting proposed CMS payment cuts and prior authorization issues.
Listen
The Departments of Health and Human Services (HHS), Labor, and the Treasury, released final rules on short-term, limited-duration insurance (STLDI) and independent, non-coordinated excepted benefits coverage, addressing issues related to the low-quality insurance, or "junk insurance" plans.
Read More
In this first part of a two-part podcast episode, Managed Healthcare Executive's Managing Editor Peter Wehrwein kicks off our new podcast series "DC Roundtable," with guests Margaret "Meg" Murray, CEO of the Association of Community Affiliated Plans, and member of MHE's Editorial Advisory Board, and Ceci Connolly, president and CEO of the Alliance of Community Health Plans, for a discussion on healthcare policy issues.
Listen
2024 Emerging Leaders in Healthcare — Submit For a Chance to Be Featured in MHE's August Issue
March 28th 2024MHE Editors are seeking diverse healthcare professionals from different backgrounds and healthcare sectors, with individual interests. Eligible candidates are early or mid-career leaders with less than 10 years of experience. Award winners will enjoy complimentary passes to the PBMI Annual National Meeting in Orlando, Florida, from Sept. 4-6. Additional perks include a feature in our August issue, a subscription to MHE and more!
Read More
Muthiah “Muthu” Vaduganathan Discusses the Role of SGLT2 Inhibitors in Heart Failure Treatment
March 27th 2024Editors of Managed Healthcare Executive spoke with Muthiah “Muthu” Vaduganathan MD, MPH, consultant cardiologist at Brigham and Women's Hospital and a member of faculty at Harvard Medical School, about the evolving treatment landscape for heart failure, emphasizing the use of SGLT2 inhibitors alongside other foundational therapies.
Read More